- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC), Daniel Spratt presents the evidence for metastasis directed therapy (MDT) in patients with synchronous and metachronous metastatic hormone sensitive prostate cancer (mHSPC). Biographies: Daniel Spratt, MD, Vincent K. Smith Chair in Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University Schoo...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC), Piet Ost presents predictors for the successful treatment of patients with oligometastatic and oligoprogressive prostate cancer, Biographies: Piet Ost, MD, PhD, associate professor at Ghent University, Ghent, Belgium, and radiation oncologist at the Iridium Network, Antwerp, Belgium Related Content: APCCC 2022: Are There Predictors...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Alicia Morgans presents the treatment of vulnerable/frail patients with metastatic hormone sensitive prostate cancer (mHSPC). Biographies: Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts Related Content: APCCC...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC), Mary Ellen Taplin presents the role of systemic therapy in the treatment of patients with oligometastatic and oligoprogressive prostate cancer. Biographies: Mary Ellen Taplin, MD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA Related Content: APCCC 2022: What Is the Evidence of Systemic Therapies (Alone or in Com...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference, Declan Murphy presents the impact of histology variants (ductal/intraductal/cribriform) on treatment recommendations. Biographies: Declan Murphy, MB, BCh, BaO, FRACS, FRCS Urol, Professor, Urologist & Director of GU Oncology, Peter MacCallum Cancer Centre, Associate Editor, BJUI, Honorary Clinical Professor, The University of Melbourne Rel...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC), Emmanuel Antonarakis provided an update on the role of immune checkpoint inhibitors in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Biographies: Emmanuel Antonarakis, MD, Clark Endowed Professor of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota Rela...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Caroline Clarke presents on health economics in metastatic hormone sensitive prostate cancer (mHSPC). Biographies: Caroline S. Clarke, PhD, MSci, BA (Hons), Senior Research Associate in Health Economics, University College London, London, UK Related Content: APCCC 2022: Optimal Treatment for mHSPC from a Health Econo...
|
- Details
- Eric Small presents a discussion on primary small cell prostate cancer and therapeutic approaches to consider in aggressive variant prostate cancer (AVPC) and small cell neuroendocrine prostate cancer (t-SCNC) patients. Biographies: Eric Small, MD, Doris and Donald Fisher Distinguished Professorship in Clinical Cancer Research; Stanford W. Ascherman and Norman R. Ascherman Endowed Chair, UCSF, Pro...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference, Noel Clarke presents the role of PARP inhibitors for all patients with metastatic castration-resistant prostate cancer (mCRPC). Biographies: Noel Clarke, MBBS, FRCS, ChM, Professor of Urological Oncology, Salford Royal Hospital & The Christie NHS Foundation Trust, Manchester, UK Related Content: APCCC 2022: Debate: PARP Inhibitors for All...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Heather Cheng presents the importance of lifestyle and prevention of complications in advanced prostate cancer, focusing on how we should take care of our patient’s muscle strength. Biographies: Heather H. Cheng, MD, PhD, Director, Seattle Cancer Care Alliance Prostate Cancer Genetics Clinic, Division of Medical Onco...
|
